Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Carisma Therapeutics, Inc. - Common Stock (NQ: CARM )

0.4200 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 30
Open 0.4200
Bid (Size) 0.4200 (1)
Ask (Size) 0.4580 (12)
Prev. Close 0.4200
Today's Range 0.4200 - 0.4200
52wk Range 0.3800 - 2.660
Shares Outstanding N/A
Dividend Yield 85.95%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill

Performance

YTD
-4.57%
-4.57%
1 Month
-4.15%
-4.15%
3 Month
-24.50%
-24.50%
6 Month
-57.98%
-57.98%
1 Year
-82.79%
-82.79%

More News

Read More
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
In-Depth Examination Of 5 Analyst Recommendations For CARISMA Therapeutics
Via Benzinga
The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts
Via Benzinga
The Latest Analyst Ratings for CARISMA Therapeutics
Via Benzinga
Why Are Carisma Therapeutics Shares Surging Friday?
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
CARM Stock Earnings: CARISMA Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
What 5 Analyst Ratings Have To Say About CARISMA Therapeutics
Via Benzinga
Analyst Ratings for CARISMA Therapeutics
Via Benzinga
3 Top Under-$5 Stocks for Strong Gains and Positive Outlook
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023
Via Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023
Via Benzinga
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.